Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Orbimed Advisors Llc is Director at Disc Medicine. OQRO lists 101 transactions filed with the SEC under this name, the latest on Nov 11, 2026, each linked to the official Form 4.
Director
Disclosures on record
101
Companies involved
17
6 buys, median −44.0 pts vs S&P 500, beat it 2 of 6 times.
Average −20.5 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Oct 17, 2024 to Aug 12, 2026, measured from the first close after the filing. Past results, not a forecast.
Electra TherapeuticsETRA
16 disclosures · Nov 2026 · 16 bought
Nov 6, 2026Bought~$311Kdisclosed Nov 11
DetailsOfficial recordNov 10, 2026Bought~$175Kdisclosed Nov 11
DetailsNov 9, 2026Bought~$132Kdisclosed Nov 11
DetailsOfficial recordNov 6, 2026Bought~$77Kdisclosed Nov 11
DetailsOfficial recordNov 9, 2026Bought~$33Kdisclosed Nov 11
DetailsOfficial recordNov 10, 2026Bought~$17Kdisclosed Nov 11
DetailsOfficial recordNov 5, 2026Bought~$915K
DetailsOfficial recordNov 3, 2026Bought~$767Kdisclosed Nov 5
DetailsOfficial recordNov 3, 2026Bought~$777Kdisclosed Nov 5
DetailsOfficial recordNov 4, 2026Bought~$289Kdisclosed Nov 5
DetailsOfficial recordNov 5, 2026Bought~$226K
DetailsOfficial recordNov 3, 2026Bought~$192Kdisclosed Nov 5
DetailsOfficial recordNov 3, 2026Bought~$191Kdisclosed Nov 5
DetailsOfficial recordNov 4, 2026Bought~$141Kdisclosed Nov 5
DetailsOfficial recordNov 4, 2026Bought~$72Kdisclosed Nov 5
DetailsOfficial recordNov 4, 2026Bought~$35Kdisclosed Nov 5
DetailsOfficial recordAspen NeuroscienceASPE
11 disclosures · Nov 2026 · 1 bought
Nov 2, 2026Bought~$15Mdisclosed Nov 4
DetailsOfficial recordNov 2, 2026197Kdisclosed Nov 4
DetailsOfficial recordNov 2, 2026643Kdisclosed Nov 4
DetailsOfficial recordNov 2, 2026617Kdisclosed Nov 4
DetailsOfficial recordNov 2, 2026626Kdisclosed Nov 4
DetailsOfficial recordNov 2, 2026507Kdisclosed Nov 4
DetailsOfficial recordNov 2, 2026197Kdisclosed Nov 4
DetailsOfficial recordNov 2, 2026643Kdisclosed Nov 4
DetailsOfficial recordNov 2, 2026617Kdisclosed Nov 4
DetailsOfficial recordNov 2, 2026626Kdisclosed Nov 4
DetailsOfficial recordNov 2, 2026507Kdisclosed Nov 4
DetailsOfficial recordTraws PharmaTRAW
4 disclosures · Apr 2026 · 1 bought
Apr 16, 2026Bought~$998Kdisclosed Apr 29
DetailsOfficial recordApr 16, 2026598Kdisclosed Apr 29
DetailsOfficial recordApr 16, 2026598Kdisclosed Apr 29
DetailsOfficial recordApr 16, 20261.79Mdisclosed Apr 29
DetailsOfficial recordImagenebioIMA
2 disclosures · Apr 2026
Apr 14, 2026337Kdisclosed Apr 16
DetailsOfficial recordApr 14, 2026385Kdisclosed Apr 16
DetailsOfficial recordKeros TherapeuticsKROS
2 disclosures · Dec 2025
Nov 21, 2025140Kdisclosed Dec 18
DetailsOfficial recordNov 21, 202574Kdisclosed Dec 18
DetailsOfficial recordSep 10, 2025Sold~$900Kdisclosed Sep 12
DetailsOfficial recordShattuck LabsSTTK
2 disclosures · Sep 2025 · 2 bought
Aug 25, 2025Bought~$4.56Mdisclosed Sep 3
DetailsOfficial recordAug 25, 2025Bought~$912Kdisclosed Sep 3
DetailsOfficial recordJun 27, 2025Sold~$4.89Mdisclosed Jul 2
DetailsOfficial recordPassage BioPASG
21 disclosures · Dec 2024 – Jun 2025 · 21 sold
Jun 24, 2025Sold~$81Kdisclosed Jun 26
DetailsOfficial recordJun 26, 2025Sold~$70K
DetailsOfficial recordJun 25, 2025Sold~$46Kdisclosed Jun 26
DetailsOfficial recordApr 23, 2025Sold~$30Kdisclosed Apr 24
DetailsOfficial recordApr 22, 2025Sold~$27Kdisclosed Apr 24
DetailsOfficial recordApr 24, 2025Sold~$22K
DetailsOfficial recordApr 17, 2025Sold~$25K
DetailsOfficial recordApr 16, 2025Sold~$20Kdisclosed Apr 17
DetailsOfficial recordApr 15, 2025Sold~$3.9Kdisclosed Apr 17
DetailsOfficial recordJan 10, 2025Sold~$83Kdisclosed Jan 14
DetailsOfficial recordJan 14, 2025Sold~$47K
DetailsOfficial recordJan 13, 2025Sold~$12Kdisclosed Jan 14
DetailsOfficial recordJan 8, 2025Sold~$51K
DetailsOfficial recordJan 7, 2025Sold~$37Kdisclosed Jan 8
DetailsOfficial recordJan 6, 2025Sold~$15Kdisclosed Jan 8
DetailsOfficial recordDec 20, 2024Sold~$138Kdisclosed Dec 26
DetailsOfficial recordDec 9, 2024Sold~$46Kdisclosed Dec 11
DetailsOfficial recordDec 10, 2024Sold~$6.4Kdisclosed Dec 11
DetailsOfficial recordDec 11, 2024Sold~$64
DetailsOfficial recordDec 4, 2024Sold~$60Kdisclosed Dec 7
DetailsOfficial recordDec 6, 2024Sold~$17Kdisclosed Dec 7
DetailsOfficial recordNeuropaceNPCE
2 disclosures · May 2025 · 2 sold
May 14, 2025Sold~$2.12Mdisclosed May 16
DetailsOfficial recordMay 14, 2025Sold~$542Kdisclosed May 16
DetailsOfficial recordXtant Medical HoldingsXTNT
2 disclosures · Apr 2025 · 2 sold
Apr 10, 2025Sold~$23.5Mdisclosed Apr 14
DetailsOfficial recordApr 10, 2025Sold~$7.19Mdisclosed Apr 14
DetailsOfficial recordApr 9, 2025Sold~$5.68Mdisclosed Apr 11
DetailsOfficial recordEdgewise TherapeuticsEWTX
2 disclosures · Apr 2025 · 2 bought
Apr 3, 2025Bought~$7.5Mdisclosed Apr 4
DetailsOfficial recordApr 3, 2025Bought~$2.5Mdisclosed Apr 4
DetailsOfficial recordDisc MedicineIRON
27 disclosures · Mar 2025 · 27 sold
Mar 24, 2025Sold~$164Kdisclosed Mar 26
DetailsOfficial recordMar 24, 2025Sold~$106Kdisclosed Mar 26
DetailsOfficial recordMar 24, 2025Sold~$41Kdisclosed Mar 26
DetailsOfficial recordMar 19, 2025Sold~$1.13Mdisclosed Mar 22
DetailsOfficial recordMar 19, 2025Sold~$730Kdisclosed Mar 22
DetailsOfficial recordMar 19, 2025Sold~$282Kdisclosed Mar 22
DetailsOfficial recordMar 21, 2025Sold~$285Kdisclosed Mar 22
DetailsOfficial recordMar 21, 2025Sold~$184Kdisclosed Mar 22
DetailsOfficial recordMar 20, 2025Sold~$79Kdisclosed Mar 22
DetailsOfficial recordMar 21, 2025Sold~$71Kdisclosed Mar 22
DetailsOfficial recordMar 20, 2025Sold~$51Kdisclosed Mar 22
DetailsOfficial recordMar 20, 2025Sold~$20Kdisclosed Mar 22
DetailsOfficial recordMar 10, 2025Sold~$5.78Mdisclosed Mar 13
DetailsOfficial recordMar 10, 2025Sold~$3.73Mdisclosed Mar 13
DetailsOfficial recordMar 12, 2025Sold~$2.34Mdisclosed Mar 13
DetailsOfficial recordMar 12, 2025Sold~$1.51Mdisclosed Mar 13
DetailsOfficial recordMar 10, 2025Sold~$1.44Mdisclosed Mar 13
DetailsOfficial recordMar 11, 2025Sold~$771Kdisclosed Mar 13
DetailsOfficial recordMar 12, 2025Sold~$584Kdisclosed Mar 13
DetailsOfficial recordMar 11, 2025Sold~$498Kdisclosed Mar 13
DetailsOfficial recordMar 11, 2025Sold~$193Kdisclosed Mar 13
DetailsOfficial recordMar 12, 2025Sold~$51Kdisclosed Mar 13
DetailsOfficial recordMar 12, 2025Sold~$33Kdisclosed Mar 13
DetailsOfficial recordMar 12, 2025Sold~$13Kdisclosed Mar 13
DetailsOfficial recordMar 10, 2025Sold~$12Kdisclosed Mar 13
DetailsOfficial recordMar 10, 2025Sold~$7.5Kdisclosed Mar 13
DetailsOfficial recordMar 10, 2025Sold~$2.9Kdisclosed Mar 13
DetailsOfficial recordMbx BiosciencesMBX
4 disclosures · Feb 2025 · 4 bought
Feb 18, 2025Bought~$1.02Mdisclosed Feb 19
DetailsOfficial recordFeb 18, 2025Bought~$532Kdisclosed Feb 19
DetailsOfficial recordFeb 14, 2025Bought~$291Kdisclosed Feb 19
DetailsOfficial recordFeb 14, 2025Bought~$178Kdisclosed Feb 19
DetailsOfficial recordFeb 10, 2025Bought~$9.9M
DetailsOfficial recordUpstream BioUPB
2 disclosures · Oct 2024 · 2 bought
Oct 15, 2024Bought~$11.2Mdisclosed Oct 17
DetailsOfficial recordOct 15, 2024Bought~$2.81Mdisclosed Oct 17
DetailsOfficial recordAs of the latest filing on , Orbimed Advisors Llc reported holding 7,165,006 shares of Corvus Pharmaceuticals (CRVS), worth about $76.2M at the last close of $11 (Nov 13, 2026), held through a see footnotes. Holdings are also on file at Aspen Neuroscience (ASPE), Mbx Biosciences (MBX), Blossomhill Therapeutics (BLSM), Passage Bio (PASG), Neuropace (NPCE), Edgewise Therapeutics (EWTX), Electra Therapeutics (ETRA), Disc Medicine (IRON), Upstream Bio (UPB), Sionna Therapeutics (SION), Adarx Pharmaceuticals (ADRX), Pmv Pharmaceuticals (PMVP), Shattuck Labs (STTK), Keros Therapeutics (KROS), Traws Pharma (TRAW); together they are worth about $352M. In the last 12 months, Orbimed Advisors Llc bought $20.3M in 18 open-market purchases.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Corvus Pharmaceuticals CRVS | 7,165,006 | 7.17M see footnotes | $11 | $76.2M | Jun 27, 2025 |
| Aspen Neuroscience ASPE | 3,589,132 | 3.59M see footnotes | $13 | $45.2M | Nov 2, 2026 |
| Mbx Biosciences MBX | 747,887 | 748K see footnotes | $56 | $41.8M | Feb 18, 2025 |
| Blossomhill Therapeutics BLSM | 2,714,279 | 2.71M see footnotes | $14 | $38.1M | Aug 10, 2026 |
| Passage Bio PASG | 6,066,343 | 6.07M see footnotes | $4 | $25.8M | Jun 26, 2025 |
| Neuropace NPCE | 3,238,199 | 3.24M see footnotes | $8 | $24.5M | May 14, 2025 |
| Edgewise Therapeutics EWTX | 443,792 | 444K see footnotes | $46 | $20.4M | Apr 3, 2025 |
| Electra Therapeutics ETRA | 2,194,579 | 2.19M see footnotes | $9 | $19.4M | Nov 10, 2026 |
| Disc Medicine IRON | 186,541 | 187K see footnotes | $80 | $14.9M | Mar 24, 2025 |
| Upstream Bio UPB | 4,554,873 | 4.55M see footnote | $3 | $12.7M | Oct 15, 2024 |
| Sionna Therapeutics SION | 3,704,959 | 3.70M see footnotes | $3 | $12.3M | Feb 10, 2025 |
| Adarx Pharmaceuticals ADRX | 588,235 | 588K see footnotes | $14 | $8.35M | Sep 28, 2026 |
| Pmv Pharmaceuticals PMVP | 4,975,291 | 4.98M see footnotes | $1 | $6.32M | Oct 23, 2025 |
| Shattuck Labs STTK | 1,051,021 | 1.05M see footnote | $5 | $4.89M | Aug 25, 2025 |
| Keros Therapeutics KROS | 45,057 | 45K see footnotes | $10 | $464K | Nov 21, 2025 |
| Traws Pharma TRAW | 1,203,250 | 1.20M see footnote | $0 | $302K | Apr 16, 2026 |
Is this Orbimed Advisors Llc’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Jun 27, 2025, Orbimed Advisors Llc reported holding 7,165,006 shares of Corvus Pharmaceuticals (CRVS), held indirectly. At the last close of $11 on Nov 13, 2026, that is about $76.2M. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Orbimed Advisors Llc reported 18 open-market purchases worth $20.3M, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Orbimed Advisors Llc bought shares on the open market in 12 different years since 2011 across 33 companies. Sales in each of the last 3 years.
In SEC filings since 2011: the latest open-market purchase is from 2026; the latest open-market sale is from 2025.
33 companies: Electra Therapeutics (ETRA, 2026), Aspen Neuroscience (ASPE, 2026), Traws Pharma (TRAW, 2026), Disc Medicine (IRON, 2023–2025), Passage Bio (PASG, 2022–2025) and others.
Orbimed Advisors Llc bought shares on the open market in 12 different years since 2011 across 33 companies. Sales in each of the last 3 years.
Orbimed Advisors Llc reported 94 open-market purchases and 168 sales since 2011; purchases in 12 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $20.3M18×18 trades | — |
| 2025 | $27.4M9×9 trades | $65.5M49×49 trades |
| 2024 | $26M4×4 trades | $3.66M17×17 trades |
| 2023 | $5.33M9×9 trades | $1.92M12×12 trades |
| 2022 | $1.96M5×5 trades | — |
| 2021 | $22.2M5×5 trades | $12.5M8×8 trades |
| 2020 | $52.8M6×6 trades | $133M28×28 trades |
| 2019 | $15.3M7×7 trades | $57.2M22×22 trades |
| 2018 | $28M13×13 trades | $33.1M16×16 trades |
| 2017 | $564K3×3 trades | — |
| 2016 | $16.8M11×11 trades | $9.87M6×6 trades |
| 2012 | — | $7.97M2×2 trades |
| 2011 | $3.75M4×4 trades | $1.82M8×8 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Orbimed Advisors Llc reported 3 open-market purchases and 36 sales here, 2019 to 2020.
Orbimed Advisors Llc reported 3 open-market purchases and 27 sales here, 2023 to 2025.
Orbimed Advisors Llc reported 3 open-market purchases and 22 sales here, 2022 to 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
